The burgeoning popularity of tirzepatide , initially for diabetes , is creating significant buzz within the United Kingdom , prompting a notable shift in hormone trends. Availability these medications remains a complex challenge , with National Health Service provision currently limited and independent providers offering therapy at a higher cost .